Buprenorphine is under clinical development by IX Biopharma and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Buprenorphine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Buprenorphine (BnoX) is under development for the treatment of acute and severe pain. The therapeutic candidate is formulated as a wafer and is administered through sublingual route. The drug candidate acts by targeting mu-opioid receptor and kappa receptor. The drug candidate is developed based on the WaferiX sublingual technology. It was also under development for the treatment of opioid addiction.
IX Biopharma overview
iX Biopharma is a pharmaceutical and nutraceutical company. It discover, develops and commercializes novel therapies to treat diseases targeting central nervous system. The company’s products include Wafesil, a sublingual oral wafer containing sildenafil citrate and Silcap, an oral ingestion containing sildenafil citrate for the treatment of male erectile dysfunction. iX Biopharma provides pipeline products such as Wafermine, a sublingual ketamine oral wafer used to manage moderate to severe pain and pioid analgesia, Xativa, a sublingual wafer containing cannabidiol (CBD) against anxiety, movement disorder and chronic inflammation condition. BnoX, a sublingual buprenorphine oral wafer for pain management and Wafernyl, a sublingual fentanyl oral wafer used in breakthrough of cancer pain. iX Biopharma utilizes its proprietary formulation Waferix Sublingual to develop its products. The company conducts its research and development activities in Singapore and Australia. iX Biopharma is headquartered in Singapore.
For a complete picture of Buprenorphine’s drug-specific PTSR and LoA scores, buy the report here.